Comparing Anti-hepatitis B Antibody Level in Iranian Obese or Overweight with Non-obese Cases

BACKGROUND: There is a controversy about the relation between anti-hepatitis B (anti-HBs) antibody level and obesity. We designed this study to compare the vaccine efficacy in obese/overweight and non-obese cases. METHODS: In this cross-sectional study, 242 obese/overweight and 85 non-obese individu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kabir, Ali, Pazouki, Abdolreza, Jafari, Motahareh, Mokhber, Somayye, Vaziri, Mohammad, Alavian, Seyed Moayed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pasteur Institute 2017
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392223/
https://www.ncbi.nlm.nih.gov/pubmed/27805073
http://dx.doi.org/10.18869/acadpub.ibj.21.3.197
_version_ 1783229405041000448
author Kabir, Ali
Pazouki, Abdolreza
Jafari, Motahareh
Mokhber, Somayye
Vaziri, Mohammad
Alavian, Seyed Moayed
author_facet Kabir, Ali
Pazouki, Abdolreza
Jafari, Motahareh
Mokhber, Somayye
Vaziri, Mohammad
Alavian, Seyed Moayed
author_sort Kabir, Ali
collection PubMed
description BACKGROUND: There is a controversy about the relation between anti-hepatitis B (anti-HBs) antibody level and obesity. We designed this study to compare the vaccine efficacy in obese/overweight and non-obese cases. METHODS: In this cross-sectional study, 242 obese/overweight and 85 non-obese individuals were participated. Cases were selected from a referral clinic for obesity and a referral hepatology clinic, both in Tehran, Iran. RESULTS: Obese cases had lower percentage of liver diseases (66.9% vs. 100%, P<0.001) but higher percentage of hepatitis B vaccination history (74.9% vs. 51.2%, P<0.001). Median±inter-quartile range of anti-HBs titer in obese cases was significantly lower than controls (48.5±194.5 vs. 100±557.6, P=0.012). CONCLUSION: The level of anti-HBs surface antigen antibody’s titer in obese cases without liver disease is lower than control group. Therefore, a suitable strategy is needed to overcome this problem, which can be the use of longer needles for vaccination.
format Online
Article
Text
id pubmed-5392223
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Pasteur Institute
record_format MEDLINE/PubMed
spelling pubmed-53922232017-05-01 Comparing Anti-hepatitis B Antibody Level in Iranian Obese or Overweight with Non-obese Cases Kabir, Ali Pazouki, Abdolreza Jafari, Motahareh Mokhber, Somayye Vaziri, Mohammad Alavian, Seyed Moayed Iran Biomed J Short Communication BACKGROUND: There is a controversy about the relation between anti-hepatitis B (anti-HBs) antibody level and obesity. We designed this study to compare the vaccine efficacy in obese/overweight and non-obese cases. METHODS: In this cross-sectional study, 242 obese/overweight and 85 non-obese individuals were participated. Cases were selected from a referral clinic for obesity and a referral hepatology clinic, both in Tehran, Iran. RESULTS: Obese cases had lower percentage of liver diseases (66.9% vs. 100%, P<0.001) but higher percentage of hepatitis B vaccination history (74.9% vs. 51.2%, P<0.001). Median±inter-quartile range of anti-HBs titer in obese cases was significantly lower than controls (48.5±194.5 vs. 100±557.6, P=0.012). CONCLUSION: The level of anti-HBs surface antigen antibody’s titer in obese cases without liver disease is lower than control group. Therefore, a suitable strategy is needed to overcome this problem, which can be the use of longer needles for vaccination. Pasteur Institute 2017-05 /pmc/articles/PMC5392223/ /pubmed/27805073 http://dx.doi.org/10.18869/acadpub.ibj.21.3.197 Text en Copyright: © Iranian Biomedical Journal http://creativecommons.org/licenses/by/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Kabir, Ali
Pazouki, Abdolreza
Jafari, Motahareh
Mokhber, Somayye
Vaziri, Mohammad
Alavian, Seyed Moayed
Comparing Anti-hepatitis B Antibody Level in Iranian Obese or Overweight with Non-obese Cases
title Comparing Anti-hepatitis B Antibody Level in Iranian Obese or Overweight with Non-obese Cases
title_full Comparing Anti-hepatitis B Antibody Level in Iranian Obese or Overweight with Non-obese Cases
title_fullStr Comparing Anti-hepatitis B Antibody Level in Iranian Obese or Overweight with Non-obese Cases
title_full_unstemmed Comparing Anti-hepatitis B Antibody Level in Iranian Obese or Overweight with Non-obese Cases
title_short Comparing Anti-hepatitis B Antibody Level in Iranian Obese or Overweight with Non-obese Cases
title_sort comparing anti-hepatitis b antibody level in iranian obese or overweight with non-obese cases
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392223/
https://www.ncbi.nlm.nih.gov/pubmed/27805073
http://dx.doi.org/10.18869/acadpub.ibj.21.3.197
work_keys_str_mv AT kabirali comparingantihepatitisbantibodyleveliniranianobeseoroverweightwithnonobesecases
AT pazoukiabdolreza comparingantihepatitisbantibodyleveliniranianobeseoroverweightwithnonobesecases
AT jafarimotahareh comparingantihepatitisbantibodyleveliniranianobeseoroverweightwithnonobesecases
AT mokhbersomayye comparingantihepatitisbantibodyleveliniranianobeseoroverweightwithnonobesecases
AT vazirimohammad comparingantihepatitisbantibodyleveliniranianobeseoroverweightwithnonobesecases
AT alavianseyedmoayed comparingantihepatitisbantibodyleveliniranianobeseoroverweightwithnonobesecases

Ejemplares similares